Petros Pharmaceuticals Share Price

Equities

PTPI

US71678J2096

Market Closed - Nasdaq 01:30:00 27/04/2024 am IST 5-day change 1st Jan Change
0.6399 USD 0.00% Intraday chart for Petros Pharmaceuticals -4.51% -54.62%
Sales 2024 * 5.66M 472M Sales 2025 * 5.67M 473M Capitalization 4.4M 367M
Net income 2024 * -12M -1B Net income 2025 * -13M -1.08B EV / Sales 2024 * 0.78 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.78 x
P/E ratio 2024 *
-0.11 x
P/E ratio 2025 *
-0.15 x
Employees 21
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Petros, Lemonaid Health Collaborate to Expand Stendra Availability MT
Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health CI
Petros Gets 'Positive' FDA Response Over Technology Component in Stendra OTC Process MT
Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R) CI
Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA as it Pursues OTC Status CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider CI
Top Premarket Gainers MT
Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study CI
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) the First Erectile Dysfunction Medication to Achieve OTC Status CI
Maxim Initiates Petros Pharma at Buy Rating With $4 Price Target MT
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug Crestor's (Rosuvastatin) OTC Switch Technology Provider CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Petros Pharmaceuticals Announces to Develop Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R) CI
Petros Pharmaceuticals, Inc. Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA CI
More news
1 week-4.51%
Current month-56.76%
1 month-58.72%
3 months-41.83%
6 months-59.24%
Current year-54.62%
More quotes
1 week
0.60
Extreme 0.602
0.71
1 month
0.60
Extreme 0.602
1.52
Current year
0.60
Extreme 0.602
2.27
1 year
0.60
Extreme 0.602
5.24
3 years
0.60
Extreme 0.602
52.00
5 years
0.60
Extreme 0.602
59.60
10 years
0.60
Extreme 0.602
59.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 -
President 47 01/20/01
Comptroller/Controller/Auditor 61 01/19/01
Members of the board TitleAgeSince
Chief Executive Officer 61 -
Director/Board Member 60 01/20/01
Director/Board Member 53 01/20/01
More insiders
Date Price Change Volume
26/24/26 0.6399 0.00% 77,235
25/24/25 0.6399 +0.87% 225,361
24/24/24 0.6344 -6.72% 188,126
23/24/23 0.6801 +4.60% 615,206
22/24/22 0.6502 -2.97% 211,595

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes
Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics with a range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The Company is also focused on identifying, developing, acquiring, and commercializing therapeutics for men's health issues, including, erectile dysfunction (ED), endothelial dysfunction, psychosexual and psychosocial ailments, peyronie's disease, hormone health, and substance use disorders. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products, the Company is focused on identifying and developing other pharmaceuticals to advance men's health, which is H100, which is the topical formulation candidate for the treatment of acute peyronie's disease.
Sector
-
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.6399 USD
Average target price
4 USD
Spread / Average Target
+525.10%
Consensus